

# L-citrulline to Improve Adverse Outcomes in Admitted Children (EChLiBRiST, Clinical Trial 2, Inpatients)

NCT06426147

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Not Applicable
<b>Sponsor</b>	Barcelona Institute for Global Health
<b>Enrollment</b>	2,200 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Enrolled in the initial prognostic screening component.
- Sick children with fever (axillary temperature  $\geq 37.5^{\circ}\text{C}$ ) or a history of fever (within the preceding 72h) or with suspected severe disease.
- $m \leq 60$  months of age.
- With an indication for admission, or having already been admitted to hospital due to their illness.
- With an sTREM-1 PoC result classifying their disease as of "moderate-high risk" ("yellow" or "red") upon study recruitment and within D3.

... and 3 more (see full listing online)

### Exclusion (8)

- Admission to hospital for social reasons (and not on account of their disease).
- Children for which informed consent document has not been signed.
- Known allergy or contraindication to any of the study supplements including lactose intolerance or observing a lactose-free diet.
- Concurrent participation in any other clinical trial.
- Patient under NPO or "nothing by mouth" prescription .

... and 3 more (see full listing online)

## Locations (2 total)

---

Hararghe Health Research, Harar, Ethiopia  
Hospital Central de Maputo, Maputo, Mozambique